LENZ reports Q2 2026 results as VIZZ adds telehealth access and global filings expand

LENZ Therapeutics reported second quarter 2026 financial results on August 11, 2026, covering VIZZ (aceclidine ophthalmic solution) 1.44%, its presbyopia eye drop. In July 2026 the company launched a telehealth prescribing option intended to speed patient access to VIZZ, combining online evaluation by independent licensed eye care providers with e-pharmacy fulfillment and home delivery, alongside existing access through eye care professionals.¹ That same month, LENZ also began a nationwide TV campaign featuring Sarah Jessica Parker as brand spokesperson.¹

On the regulatory front, LENZ submitted a Marketing Authorization Application to the UK's Medicines and Healthcare products Regulatory Agency in April 2026 for VIZZ in adult presbyopia, following the European Medicines Agency's validation of the MAA in March 2026.¹ In June 2026, LENZ signed an exclusive license and commercialization deal with Arrotex Pharmaceuticals covering Australia and New Zealand, its fifth ex-U.S. partnership, under which LENZ received an upfront payment and is eligible for a mid double-digit profit share of gross margin.¹ Also in June 2026, LENZ hit its first milestone under its agreement with Laboratoires Théa by filing a New Drug Submission with Health Canada, with up to $65 million in further milestones and tiered double-digit royalties possible.¹ In July 2026, an MAA for Saudi Arabia was submitted under Lunatus's distribution agreement, marking VIZZ's ninth ex-U.S. regulatory filing.¹

On finances, cash, cash equivalents and marketable securities stood at $220.0 million as of June 30, 2026.¹ Product revenue for the quarter was over $1.7 million on about 27,000 packs sold, a 9% rise from Q1 2026.¹ Net loss for the quarter was $31.9 million, or $1.02 per share.¹